

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
C. Jane ROBINSON et al.) Group Art Unit: To Be Assigned
)
Serial No.: To Be Assigned) Examiner: To Be Assigned
)
Filed: Herewith)
)
For: Antithrombin III for Disorders)
Caused by Angiogenesis)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to examination of this application on its merits, please amend the application as follows:

IN THE ABSTRACT:

After line 5, delete "Antithrombin III for disorders caused by angiogenesis"

IN THE SPECIFICATION:

Page 5, line 17, please insert

--Brief Description of the Drawings

Fig. 1 shows the effect of the alpha and beta forms of antithrombin on HUVEC cell numbers in the presence of VEGF, as determined by crystal violet staining.

FOR OFFICIAL USE ONLY

Fig. 2 shows the effect of different concentrations of antithrombin III on HUVEC proliferation as determined by an MTT assay.

Fig. 3 shows the effect of different concentrations of antithrombin III on CPAC proliferation as determined by an MTT assay.

Fig. 4 shows the effect of different concentrations of Kybernin[®]P on HUVEC proliferation as determined by an MTT assay.

Fig. 5 shows the effect of different concentrations of Kybernin[®]P on CPAC proliferation as determined by an MTT assay.

Fig. 6 shows the effect of different concentrations of Kybernin[®]P on HUVEC proliferation as determined by a BrdU assay.

Fig. 7 shows the effect of different concentrations of Kybernin[®]P on CPAC proliferation as determined by a BrdU assay.--

IN THE CLAIMS:

Please cancel claims 1-6 and add new claims 7-15, as follows:

7. (New) A method of prophylaxis for a disorder caused by angiogenesis or arteriogenesis comprising administering active antithrombin III to a patient in need thereof.

8. (New) A method of treating a disorder caused by angiogenesis or arteriogenesis comprising administering active antithrombin III to a patient in need thereof.

ATTORNEY'S OFFICE

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

9. (New) The method as claimed in claim 7 or 8, wherein the α isoform of antithrombin III, the β isoform of antithrombin III, a mixture of the two isoforms, or a concentrate of antithrombin III, is administered.

10. (New) The method as claimed in claim 7 or 8, wherein the disorder is a retinopathy, neuropathy, or an infectious disease such as leprosy.

11. (New) The method as claimed in claim 7 or 8, wherein the disorder is a cancer.

12. (New) The method as claimed in claim 11, wherein the cancer is a cancerous ulcer or a metastasis of cancerous ulcer.

13. (New) The method as claimed in claim 7 or 8, wherein the disorder is rheumatoid arthritis, psoriasis, endometriosis, chronic bronchitis, or a chronic inflammation of the gastrointestinal tract.

14. (New) The method as claimed in claim 7 or 8, wherein the antithrombin III is prepared recombinantly or transgenically.

15. (New) The method as claimed in claim 7 or 8, wherein the antithrombin III is administered intravenously, subcutaneously, intramuscularly or topically.

REMARKS

Claims 1-6 have been cancelled without prejudice or disclaimer, and new claims 7-15 have been added to more particularly point out and distinctly claim the subject matter which Applicants regard as the invention.

EFFORTS

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


Applicants respectfully request examination and timely allowance of the pending claims. Applicants submit that the pending claims are in condition for allowance, and request a prompt, favorable action on the merits.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 16, 2002

By: 

Carol P. Einaudi
Reg. No. 32,220

FOR FILING

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com